3-(17β-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide | 1014704-34-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-(17β-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide
• 英文别名: 3-[[(8R,9S,13S,14S,16R,17S)-17-hydroxy-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]methyl]benzamide
• CAS: 1014704-34-7
• 化学式: C₂₇H₃₃NO₃
• 分子量: 419.564
• InChiKey: ICBBKLWAGXRVSD-FCJCMXMISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(17β-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide 在 jones' reagent 作用下， 以 丙酮 为溶剂， 生成 3-(3-methoxy-17-oxo-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide
  参考文献：
  名称：

  Estradiol and estrone C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by estrone

  摘要：

  Estrogens play an important role in the development of breast cancer. Inhibiting 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1)-the enzyme responsible for the last step in the biosynthesis of the most potent estrogen, estradiol (E-2)-would thus allow hindering the growth of estrogen-sensitive tumors. Based on a previous study identifying 16 beta-benzyl-E-2 (1) as a lead compound for developing inhibitors of the transformation of estrone (E-1) into E-2, we modified the benzyl group of 1 to improve its inhibitory activity. Three strategies were also devised to produce compounds with less residual estrogenic activity: (1) replacing the hydroxy group by a hydrogen at position 3 (C3); (2) adding a methoxy at C2; and (3) adding an alkylamide chain known to be antiestrogenic at C7. In order to test the inhibitory potency of the new compounds, we used the human breast cancer cell line T-47D, which exerts a strong endogenous 17 beta-HSD1 activity. In this intact cell model, 16 beta-m-carbamoylbenzyl-E-2 (4m) emerged as a potent inhibitor of 17 beta-HSD1 with an IC50 value of 44 nM for the transformation of [C-14]-E-1 (60 nM) into [C-14]-E-2 (24-h incubation). In another assay aimed at assessing the unwanted estrogenic activity, a 10-day treatment with 4m at a concentration of 0.5 mu M induced some proliferation (38%) of T-47D estrogen-sensitive (ER+) breast cancer cells. Interestingly, when 4m (0.5 mu M) was given with E-1 (0.1 nM) in a 10-day treatment, it blocked 62% of the T-47D cell proliferation induced by E-1 after its reduction to E-2 by 17 beta-HSD1. Thus, in addition to generating useful structure-activity relationships for the development of 17 beta-HSD1 inhibitors, our study demonstrates that using such inhibitors is a valuable strategy for reducing the level of E-2 and consequently its proliferative effect in T-47D ER+ breast cancer cells. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.007
• 作为产物：
  描述：

  3-(3,17β-dihydroxy-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide 、 碘甲烷 在 caesium carbonate 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 3-(17β-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16β-ylmethyl)-benzamide
  参考文献：
  名称：

  Estradiol and estrone C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by estrone

  摘要：

  Estrogens play an important role in the development of breast cancer. Inhibiting 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1)-the enzyme responsible for the last step in the biosynthesis of the most potent estrogen, estradiol (E-2)-would thus allow hindering the growth of estrogen-sensitive tumors. Based on a previous study identifying 16 beta-benzyl-E-2 (1) as a lead compound for developing inhibitors of the transformation of estrone (E-1) into E-2, we modified the benzyl group of 1 to improve its inhibitory activity. Three strategies were also devised to produce compounds with less residual estrogenic activity: (1) replacing the hydroxy group by a hydrogen at position 3 (C3); (2) adding a methoxy at C2; and (3) adding an alkylamide chain known to be antiestrogenic at C7. In order to test the inhibitory potency of the new compounds, we used the human breast cancer cell line T-47D, which exerts a strong endogenous 17 beta-HSD1 activity. In this intact cell model, 16 beta-m-carbamoylbenzyl-E-2 (4m) emerged as a potent inhibitor of 17 beta-HSD1 with an IC50 value of 44 nM for the transformation of [C-14]-E-1 (60 nM) into [C-14]-E-2 (24-h incubation). In another assay aimed at assessing the unwanted estrogenic activity, a 10-day treatment with 4m at a concentration of 0.5 mu M induced some proliferation (38%) of T-47D estrogen-sensitive (ER+) breast cancer cells. Interestingly, when 4m (0.5 mu M) was given with E-1 (0.1 nM) in a 10-day treatment, it blocked 62% of the T-47D cell proliferation induced by E-1 after its reduction to E-2 by 17 beta-HSD1. Thus, in addition to generating useful structure-activity relationships for the development of 17 beta-HSD1 inhibitors, our study demonstrates that using such inhibitors is a valuable strategy for reducing the level of E-2 and consequently its proliferative effect in T-47D ER+ breast cancer cells. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.007